Pfizer has agreed to acquire Trillium Therapeutics for $2.26 billion, the companies said today, in a deal designed to bolster the buyer’s oncology drug portfolio by adding Trillium’s two lead molecules, both early clinical stage candidates designed to fight blood cancers by targeting CD47.
The acquisition will add to Pfizer’s pipeline Trillium’s TTI-621 and TTI-622, both designed to block a key immune checkpoint in blood cancers, the signal-regulatory protein α (SIRPα)–CD47 axis. Both SIRPα-Fc fusion proteins are now in Phase Ib/II development across several hematological malignancies.
